This year’s AIMed North America takes place in Dana Point, California between 13 and 15 December. In his opening address, AIMed founder and Chief Intelligence and Innovation Officer of Children’s Hospital of Orange County (CHOC), Dr. Anthony Chang said, artificial intelligence (AI) in medicine is not just about technology. It is also about how to deliver medicine faster, better and increase its value.
Likewise, AIMed events set out to bring physicians, clinicians, data scientists and business partners together. It is also about active exchange of opinions, forming new alliances and sharing of the latest developments. Dr. Spyro Mousses, leading scientist in genomics, system biology and machine learning and Chief Executive Officer of Systems Oncology, has seized the moment to announce the pipeline of oncology programs the company had discovered.
Systems Oncology is an AI-based biopharmaceutical company. It leverages on cognitive computing: requiring computer to mimic the way human brain works and encourages machine to have human thoughts, to mine and make sense of a more diverse biomedical datasets to uncover novel oncology medicine.
The Big Five leading to the pipeline discovery
In an interview with Dr. Mousses, he explained the five crucial steps behind the discovery of these pipeline. The initial mining phase includes an extensive search of databases to formulate new hypotheses and opportunities. The integration of all data sets took place over the course of two years before they were finalized and developed.
Thereafter, based on what has been developed, new IP will either be filed or acquired. For example, one drug in the pipeline; IB-DNQ, which targets cancer metabolism, was developed in partnership with the University of Illinois. Candidates in the pipeline will undergo checks and quality control before the final step which is seeking of pharmaceutical partner to kick start clinical trials.
Systems Oncology’s announcement closely follows the launch of ExpansiveAI project this September. ExpansiveAI is an open conglomerate the company has created for experts from diverse backgrounds with a common goal of developing a new form of AI capability known as “machine imagination”. “Imagination” refers to the computational capability of generating hypothesis or envisaging new models, which present AI is not capable of.
Machine plus human as the game-changer
By stimulating AI to think in the way human do, coupled with their capability of processing large amount of data at once, it will increase the number of opportunities we can look out for. After all, human imagination is limited; “It’s hard for human to see what machines or data look like because of its complex network, missing out on the ‘unknown unknown’” Dr. Mousses said.
Dr. Mousses believed showcasing the pipeline discovered with the help of AI brings a whole new model for the pharmaceutical industry.
“In the past, we started with biology and it will take us many years to find a target and discover a molecule again… Databases allow us to better understand what factors will determine the good and bad outcomes; personalizing precision medicine.”
Global precision medicine market is believed to reach an estimated 141 billion by 2026. As Systems Oncology managed to move from data mining to partnering within two years, Dr. Mousses is confident that the company is able to execute and effectively generate values in therapeutics which can help cancer patients. Following the success, Dr. Mousses aimed to scale up the current models, he set out to complete another 100 of such programs, which in time, will diversify the risks and positively impact the pharmaceutical industry.
A science writer with data background and an interest in current affair, culture and arts; a no-med from an (almost) all-med family. Follow on Twitter.